Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 and Comparator Seasonal Influenza Vaccines in Healthy Adults

NCT05606965 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05606965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05606965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 and Comparator Seasonal Influenza Vaccines in Healthy Adults
Lead sponsor
ModernaTX, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 2, 2022
Completion date
November 13, 2025
Enrollment
172 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza